Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
indeed! shows CEO is aware of stockholders concerns and addressing them in very transparent, friendly way.
agree, not bad CC. The team seemed excited, NH confident, that's very important. like how , quote " Epic few years ago landed us 3 or 4 mil dollars , now they are paying us 15 mil in milestone plus royalties on sales" might not be word for word but that what i remembered .
CHEERS right back at You.
looool did i just hear BUYBACK possible and NH hates reverse split, strongly belives in fundamentals!)))
like how NH started with Qs from stockholders from IR
anyone going to ask about Novel?
http://ir.elitepharma.com/events_presentations
Date: Tuesday, August 11, 2015
Time: 11:00 a.m. EDT
Webcast (live and archive) & Audio Replay: http://ir.elitepharma.com/events_presentations
Dial-in numbers: 800-346-7359 (domestic)
973-528-0008 (international)
Conference number: 98840
from 10-Q "Product development licensing increased by $5,000k due to milestone sales and distribution licensing fees earned from the Epic Collaborative Agreement, which was signed during the quarter ended June 30, 2015."
current revenues should easily gap up and support $.50-.56c PPS range
"Trademarks
We currently plan to license at least some of our products to other entities in the marketing of pharmaceuticals, but may also sell products under our own brand name in which case we may register trademarks for those products."
Sure is, doubled the operating profits..give us 3 more Q's like that and we will end the year with 10mil revenue...and that's before any ART product release
exactly my point, by the way quote from 10-Q "During the three months ended June 30, 2015, a total of 9,559,945 shares of Common Stock were sold to Lincoln Park pursuant to the Purchase Agreement, with the proceeds of such sales of Common Stock totaling $2,031,026. An additional 98,388 shares of Common Stock were issued to Lincoln Park during this same period with such shares constituting additional commitment shares issued pursuant to the Purchase Agreement."
i trade blue chip stocks for a decade now, i know the difference between diluted and currently outstanding shares valuations.
"Outstanding 659,013,790 shares"
Best Q yet !!! 7,079,772 millions in revenue looks like ELTP received the 5,000,000 part of the milestone payment from Epic...talk about FAD approval confidence.
oh and by the way, your 8.60 sell order will NOT execute at all until bid reaches 8.60..so always have to keep an eye out, seen to many orders not filled over 1 penny.
if offer comes in as usual in after hours or pre-market, then next day your shares with limit sell order will execute at market price if higher then your sell price.. lets say market opes up at 5.99 bid, then your shares will execute at 5.99 even if you had sell order of 1.99 placed a day before.
i read some here trowing around revenue numbers in billions(but i get that feeling they don't know what that would do to PPS) so before we get to billions in revenue lets check what PPS of ELTP would be with conservative low $100 million in revenue?(currently we have 5.1 millions)..ill remind you that with current valuations give us that revenue and PPS would trade at $4.92 right now....my point is: 100 mil in revenue is NOTHING if Elite successfully launches ADT
p.s
however, would bigger pharmas let Elite get that revenue? that's another question, and that's why i believe giant pharma will buyout Elite as soon as there is potential in rapid revenue growth..
from FINRA : http://regsho.finra.org/regsho-July.html
Date|Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market
20150701|ELTP|19285|0|359645|O
20150702|ELTP|121528|0|375614|O
20150706|ELTP|99253|0|430117|O
20150707|ELTP|41220|0|248302|O
20150708|ELTP|57703|0|509459|O
20150709|ELTP|288115|0|512120|O
20150710|ELTP|139915|0|379521|O
20150713|ELTP|134150|0|634867|O
20150714|ELTP|225807|0|453130|O
20150715|ELTP|282686|0|851623|O
20150716|ELTP|329400|0|575196|O
20150717|ELTP|221096|0|512474|O
20150720|ELTP|1040038|0|1963802|O
20150721|ELTP|208902|0|1313353|O
20150722|ELTP|271449|0|489018|O
there is a difference in R/S to get on NASDAQ or to stay on NASDAQ..when there is a chance to get de-listed and Co,. uses R/S to prevent it, that is bearish. But in our case it wouldn't really make any difference.
Buy 51000 ELTP Executed @ $0.2348
07/20/15 11:38 AM ET
about to slap the ask .2348 with 53,000 shares
got you, confusion might been on my part, because English is not my original language. but thanks & good luck right back at you!
ok, BUT if that's what it takes to get ADT product on the market, then i'm ok with that... plus i don't know but what was the market cap then? i was going to end my reply with last quote but ill just add this as well: comparing ELTP of 2010 vs ELTP 2015-16 is useless in my opinion. its like comparing BAC pre-crisis, crisis and post-crisis, at different times the bank had different OS, valuations and potentials.
"what one can accomplish on ones own"? are you referring that i'm bashing very same company i hold shares? i simply posted the actual numbers from 10-k filling...now, would i want for these numbers to be lower with same market cap? of course i would! does it really matter we are 100 mil OS higher? not really. recent accomplishments overweights OS increase IMO
not that difficult to read 10-k filling , i just did! to double check quote " Outstanding 631,060,701 "
recent 10-k and my etrade broker platform confirms
doesn't make much sense to use current market cap and last Q outstanding shares! lets post facts...as much as i want the outstanding shares #s to be as low as possible still no sense to fool your self with old #s
actually Outstanding Shares: 618.4 M
Added 35,000 shares @.2099 few min ago..Current PPS fully supported by revenue along..only up from here! Cheers longs!
agree, its crazy to call you crazy, and that's why you don't see the stock PPS plummeting 20% ! NH handled it exactly as i hoped he will
alright, that was actually good CC ! those few callers reminds conversation Dianne and i had, quote as close as i can remember: "professional investors believe #1 problem of current undervalued ELTP pps are those "know-it all" private shareholders base" ...if you are here for quick flip and don't believe into future billion dollar platform fundamentals, then good luck going against the MM's
extra cash = safe to say outstanding shares #s shouldn't be increasing ..no need, for now.
Epic has a state-of-the-art 110,000-square-foot development and manufacturing facility with more than 200 employees that produces more than 2 billion units (e.g., tablets, capsules, etc.) per year. Epic is located in Laurelton, New York and has revenues in excess of $120 million per year.
"Epic will pay Elite non-refundable milestone payments totaling $15 million and a royalty based on net product sales."
Royalties are commonly based on net sales rather than profits, because sales-based royalties deliver a greater guarantee that a property owner will be compensated.
with a billion in revenue and say roughly 650million outstanding shares EPS should be around $1.53 then we multiply that by x20 which is pretty conservative for bio stock and should be looking at PPS somewhere north of $30
whole .2179 is being supported by current revenue at pretty fair for BIO stock(especially an OTC)value@ 22x EPS ...im not even talking about forward EPS
just checked how on average "Significantly Regulated" Co,. trade next year and interesting fact that about half of those i check quadrupled at least(EGRX, ESPR)..others trade in range, of course there is some like Elite thats traded down but give a time for results and im sure ELTP PPS will appreciate.
(Significantly Regulated) Listing of U.S. Industries for Filing Year 2014
ELTP is in it as well, anyone else thinks NH and his team sits on his ..rear?))
Company Ticker Symbol
Eagle Pharmaceuticals, Inc. EGRX
Eastman Chemical Company EMN
Echo Therapeutics, Inc. ECTE
Ecoland International. Inc. NRBT
Ecomed Corporation IRNG
Edico Genome (private)
Edwards Lifesciences Corp EW
Egalet Ltd. EGLT
Ehouse Global, Inc. EHOS
Eisai Co., Ltd ESALY
Ekso Bionics Holdings, Inc. EKSO.OB
E. I. Du Pont De Nemours and Company DD
Elan Corporation, plc (ELN) ELN
Eldorado Artesian Springs Inc ELDO
Electrical Geodesics, Inc. EGI
Electro Scientific Industries, Inc. ESIO
Electronic Sensor Technology, Inc. ESNR
Eleven Biotherapeutics, Inc. EBIO
Eli Lilly and Company LLY
Elite Pharmaceuticals, Inc. ELTP
Elizabeth Arden, Inc. RDEN
Emerald Star Holdings, LLC GPCM
Emergent Biosolutions Inc. EBS
Emisphere Technologies, Inc. EMIS
Empire District Electric Company EDE
Enanta Pharmaceuticals, Inc. ENTA
Encision, Inc. ECIA
Endocyte, Inc. ECYT
Endologix, Inc. ELGX
Energizer Holdings, Inc. ENR
Energy Focus, Inc. EFOI
Energy Holdings International, Inc. EGYH
Enteromedics Inc. ETRM
Entia Biosciences Inc. ERGO
Envigra Inc ESRG
Environmental Tectonics Corporation ETCC
Enzo Biochem, Inc. ENZ
Enzon Pharmaceuticals, Inc. ENZN
Epirus Biopharmaceuticals, Inc. EPRS
Epizyme Inc. EPZM
Erba Diagnostics, Inc. ERB
Escalon Medical Corp. ESMC
Esperion Therapeutics, Inc. ESPR
Estee Lauder Companies Inc EL
Etablissements Delhaize Freres DEG
Evoke Pharma, Inc. EVOK
(Significantly Regulated) Listing of U.S. Industries for Filing Year 2014
ELTP is in it as well, anyone else thinks NH and his team sits on his ..rear?))
Company Ticker Symbol
Eagle Pharmaceuticals, Inc. EGRX
Eastman Chemical Company EMN
Echo Therapeutics, Inc. ECTE
Ecoland International. Inc. NRBT
Ecomed Corporation IRNG
Edico Genome (private)
Edwards Lifesciences Corp EW
Egalet Ltd. EGLT
Ehouse Global, Inc. EHOS
Eisai Co., Ltd ESALY
Ekso Bionics Holdings, Inc. EKSO.OB
E. I. Du Pont De Nemours and Company DD
Elan Corporation, plc (ELN) ELN
Eldorado Artesian Springs Inc ELDO
Electrical Geodesics, Inc. EGI
Electro Scientific Industries, Inc. ESIO
Electronic Sensor Technology, Inc. ESNR
Eleven Biotherapeutics, Inc. EBIO
Eli Lilly and Company LLY
Elite Pharmaceuticals, Inc. ELTP
Elizabeth Arden, Inc. RDEN
Emerald Star Holdings, LLC GPCM
Emergent Biosolutions Inc. EBS
Emisphere Technologies, Inc. EMIS
Empire District Electric Company EDE
Enanta Pharmaceuticals, Inc. ENTA
Encision, Inc. ECIA
Endocyte, Inc. ECYT
Endologix, Inc. ELGX
Energizer Holdings, Inc. ENR
Energy Focus, Inc. EFOI
Energy Holdings International, Inc. EGYH
Enteromedics Inc. ETRM
Entia Biosciences Inc. ERGO
Envigra Inc ESRG
Environmental Tectonics Corporation ETCC
Enzo Biochem, Inc. ENZ
Enzon Pharmaceuticals, Inc. ENZN
Epirus Biopharmaceuticals, Inc. EPRS
Epizyme Inc. EPZM
Erba Diagnostics, Inc. ERB
Escalon Medical Corp. ESMC
Esperion Therapeutics, Inc. ESPR
Estee Lauder Companies Inc EL
Etablissements Delhaize Freres DEG
Evoke Pharma, Inc. EVOK
recent(Apr 2015) Abuse-Deterrent Opioids —
Evaluation and Labeling
FDA Guidance for Industry
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf